Supernus Pharmaceuticals, Inc.
SUPN
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
14 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$50.53
Price+2.35%
$1.16
1Y
Price
Market Cap
$2.933b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+9.0%
EBITDA Margin-1.1%
Net Profit Margin+32.0%
Free Cash Flow Margin+9.0%
EBITDA Margin-1.1%
Net Profit Margin+32.0%
Free Cash Flow MarginRevenue
$776.833m
+8.1%
1y CAGR+8.5%
3y CAGR+4.2%
5y CAGREarnings
-$29.016m
+24.7%
1y CAGR+1795.1%
3y CAGR+1321.9%
5y CAGREPS
-$0.51
+25.0%
1y CAGR+2124.5%
3y CAGR+1568.9%
5y CAGRBook Value
$1.077b
$1.501b
Assets$423.920m
Liabilities$40.903m
DebtDebt to Assets
2.7%
0.9x
Debt to EBITDAFree Cash Flow
$82.245m
+78.8%
1y CAGR+20.2%
3y CAGR+13.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company